Head traumas and the majority of neurological and psychiatric diseases, such as Alzheimer‘s, Parkinson‘s, multiple sclerosis, adrenoleukodytrophy (ALD) or Charcot‘s disease are linked to direct or indirect alterations of the white matter.
Thus far, we have not identified any neurological condition that would not benefit from having an understanding of white matter integrity.
BrainTale-care platform provides reliable, reproducible and quantitative measure of the brain
Our approach is organ-specific.
Our products suite are based on brainTale-care platform
brainTale-care is a clinically evaluated software medical device available in SaaS (Software as a Service) mode for any physician with an access to a diffusion MRI:
-
We identify white matter alterations
-
We provide precision-medicine support with diagnostics, monitoring and prediction scores
-
Our ambition is to provide physicians, drug developers and hospitals with the power to provide better brain care and treatments for their patients
The BrainTale-care platform is made of two modules and one index. More modules are currently being developed by our team.
BrainQuant is being used both for white matter assessment daily as well as in clinical trials for improvement of drug developments
Use cases include potential diagnostic and monitoring of diseases
MyelinDx
A specific usage of BrainQuant data enabling myelin lesions follow up for efficient drug development
Predicts a score of coma recovery for comatose after cardiac arrest and trauma brain injuries
Provides clinicians with reliable and unprecedented information to support intensive care decision-making
BrainTale platform is supported by the European Medicine Agency through a letter of support as a new methodology for drug development and clinical endpoint
Our clients & partners
BrainTale-care platform is already used by
Velly L et al., Use of brain diffusion tensor imaging for the prediction of long-term neurological outcomes in patients after cardiac arrest: a multicentre, international, prospective, observational, cohort study. Lancet Neurol. 2018 Apr;17(4):317-326. doi: 10.1016/S1474-4422(18)30027-9
Puybasset L et al., Prognostic value of global deep white matter DTI metrics for 1-year outcome prediction in ICU traumatic brain injury patients: an MRI-COMA and CENTER-TBI combined study. Intensive Care Med. 2022 Feb;48(2):201-212. doi: 10.1007/s00134-021-06583-z
The brainTale care platform is a class IIa CE marked sofltware medical device with BSI as a notified body
It is GDPR compliant.
BrainTale is ISO 13485 certified company
« The use of BrainQuant can by no means replace a diagnosis by a licensed and competent physician nor constitute medical advice or diagnosis which can only be obtained from a physician. The physician bears the sole responsibility for the diagnosis. The calculated parameters cannot be used without medical advice from a licensed physician with competent knowledge.”
Last update : 04/20/2023